ZIM Laboratories Limited

BSE: ZIMLAB541400ISIN INE518E01015

Healthcare
Pharmaceuticals

Share price

₹134.60-7.50 (-5.28%)

as of 4 Nov 2026

Prices adjusted for splits and bonuses; cash dividends excluded. Volume shows actual shares traded.

52W high: ₹160.10
52W low: ₹59.72
Off 52W high: -15.93%
1M return: -1.21%
3M return: +17.50%
6M return: +43.91%
1Y return: +83.58%
20D avg volume: 14,515
50 DMA: ₹134.99
200 DMA: ₹103.15

Key ratios Consolidated

Market cap: ₹722.24 Cr
Current price: ₹134.60
52W high / low: ₹160.10 / ₹59.72
Face value: ₹10.00
P/E: 348.57
P/B: 2.47
EPS (TTM): ₹0.39
Book value / share: ₹54.49
ROE: —
ROCE: 6.10%
Operating margin: —
Net margin: —
Debt / equity: 0.42
Net debt: ₹97.87 Cr
Interest cover: 1.62
Dividend yield: —
Dividend / share (TTM): —
Payout: —
Cash conversion cycle: 126.6 days

Financials

Metric	Q2 FY27	Q1 FY27	Q4 FY26	Q3 FY26	Q2 FY26	Q1 FY26	Q4 FY25	Q3 FY25	Q2 FY25	Q1 FY25	Q4 FY24	Q3 FY24
Income statement
	105.45	94.18	105.27	108.66	88.71	71.76	108.73	96.33	92.14	81.82	117.86	96.29
	2.30	0.99	6.16	1.70	2.04	1.48	1.71	1.75	1.32	1.00	1.53	1.11
	107.75	95.17	111.44	110.36	90.75	73.23	110.44	98.08	93.46	82.82	119.40	97.41
	110.49	100.74	106.49	104.31	91.10	75.66	102.33	92.38	90.50	81.59	108.40	90.39
	40.84	43.82	49.70	43.23	43.50	27.62	48.60	39.88	35.52	31.01	53.49	51.51
	2.22	0.51	2.36	0.59	2.93	1.59	3.30	2.49	3.14	2.66	2.12	3.01
	19.59	19.18	17.39	15.58	16.32	14.61	16.32	14.47	15.45	14.51	14.71	13.17
	3.94	3.64	3.31	3.43	3.16	3.30	2.91	2.73	2.89	2.86	2.28	1.70
	6.53	5.37	5.10	5.03	4.98	4.86	5.29	4.88	5.00	4.94	3.90	3.94
	32.55	33.08	33.56	31.68	26.99	22.88	29.56	29.04	25.05	23.05	31.31	27.37
	-2.74	-5.57	4.94	6.05	-0.34	-2.43	8.11	5.70	2.96	1.23	11.00	7.01
	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	-2.74	-5.57	4.94	6.05	-0.34	-2.43	8.11	5.70	2.96	1.23	11.00	7.01
	-0.69	1.56	1.20	1.65	0.08	-0.56	3.22	1.70	0.58	0.34	2.91	2.23
	-2.05	-4.02	3.74	4.40	-0.42	-1.88	4.88	4.00	2.38	0.90	8.09	4.79
	-0.38	-0.75	0.76	0.90	-0.09	-0.38	1.01	0.82	0.49	0.18	1.66	0.98
Key metrics
	7.73	3.44	13.35	14.51	7.80	5.73	16.31	13.31	10.85	9.03	17.18	12.65
	7.30%	3.70%	12.70%	13.40%	8.80%	8.00%	15.00%	13.80%	11.80%	11.00%	14.60%	13.10%
	-1.90%	-4.30%	3.60%	4.00%	-0.50%	-2.60%	4.50%	4.20%	2.60%	1.10%	6.90%	5.00%
	0.30%	—	2.40%	—	0.90%	—	3.60%	—	—	—	—	—
	18.90%	31.20%	-3.20%	12.80%	-3.70%	-12.30%	-7.70%	0.00%	—	—	—	—
	-388.10%	-113.80%	-23.40%	10.00%	-117.60%	-308.90%	-39.70%	-16.50%	—	—	—	—

Metric	TTM	FY26	FY25	FY24	FY23	FY22
Income statement
	413.56	374.40	379.03	367.42	398.53	333.43
	11.15	11.38	5.78	5.18	6.41	4.40
	424.72	385.78	384.82	372.61	404.94	337.83
	422.03	377.57	366.81	348.97	369.58	316.79
	177.59	164.05	155.00	177.70	164.98	160.61
	5.68	7.47	11.58	7.80	17.39	9.41
	71.74	63.90	60.76	53.34	49.32	40.07
	14.32	13.20	11.39	6.92	5.58	8.31
	22.03	19.98	20.11	15.95	17.47	16.03
	130.87	115.11	106.70	101.31	98.38	92.03
	2.68	8.21	18.01	23.64	35.35	21.04
	0.00	0.00	0.00	0.00	0.00	0.00
	2.68	8.21	18.01	23.64	35.35	21.04
	3.72	2.38	5.84	6.40	10.92	6.49
	2.07	5.84	12.16	17.25	24.43	14.55
	0.53	1.19	2.50	3.54	5.01	8.96
Key metrics
	39.03	41.39	49.51	46.51	58.40	45.38
	9.44%	11.10%	13.10%	12.70%	14.70%	13.60%
	0.50%	1.60%	3.20%	4.70%	6.10%	4.40%
	—	6.10%	9.60%	—	—	—
	13.14%	-1.20%	3.20%	-7.80%	19.50%	—
	-68.54%	-52.00%	-29.50%	-29.40%	67.90%	—
	—	5.14	0.35	—	—	—
	—	8.48	3.38	—	—	—
	—	0.42	0.44	—	—	—
	—	97.87	110.21	—	—	—
	—	126.6	119.4	—	—	—
Balance sheet
	—	539.39	472.02	—	—	—
	—	275.81	231.31	—	—	—
	—	25.12	1.95	—	—	—
	—	109.04	106.92	—	—	—
	—	93.77	86.47	—	—	—
	—	29.10	35.12	—	—	—
	—	156.43	158.34	—	—	—
	—	72.93	69.51	—	—	—
	—	190.39	166.36	—	—	—
	—	122.99	112.16	—	—	—
	—	81.40	71.86	—	—	—
	—	41.59	40.30	—	—	—
	—	296.15	252.24	—	—	—
Cash flow
	—	49.53	41.15	—	—	—
	—	-56.35	-39.93	—	—	—
	—	28.19	-9.10	—	—	—
	—	44.39	40.80	—	—	—

Metric	Q2 FY27	Q1 FY27	Q4 FY26	Q3 FY26	Q2 FY26	Q1 FY26	Q4 FY25	Q3 FY25	Q2 FY25	Q1 FY25	Q4 FY24	Q3 FY24
Income statement
	104.22	93.05	102.85	107.81	88.39	71.43	108.52	95.39	89.72	82.00	117.39	95.82
	2.29	0.99	6.16	1.71	2.04	1.48	1.55	1.76	1.32	0.98	1.53	1.11
	106.51	94.03	109.01	109.52	90.44	72.90	110.07	97.16	91.04	82.98	118.92	96.92
	109.30	99.46	104.49	103.59	90.21	75.19	101.42	91.13	89.19	81.90	108.11	89.92
	40.84	43.82	48.85	43.23	43.50	27.62	48.60	39.88	35.52	31.01	53.49	51.51
	2.22	0.51	2.36	0.59	2.93	1.59	3.30	2.49	3.14	2.66	2.12	3.01
	18.56	18.14	16.28	14.79	15.46	13.57	15.33	13.16	14.44	13.48	14.12	12.32
	3.94	3.64	3.31	3.43	3.16	3.30	2.91	2.73	2.89	2.86	2.28	1.70
	6.26	5.17	4.90	4.85	4.83	4.79	5.23	4.77	4.97	4.92	3.87	3.58
	32.66	33.04	33.91	31.75	27.12	23.51	29.69	29.22	25.37	23.84	31.65	28.10
	-2.79	-5.42	4.53	5.93	0.23	-2.28	8.65	6.03	1.85	1.08	10.80	7.01
	0.00	0.00	0.00	0.00	0.00	0.00	0.00	—	—	—	—	—
	-2.79	-5.42	4.53	5.93	0.23	-2.28	8.65	6.03	1.85	1.08	10.80	7.01
	-0.65	1.55	1.24	1.67	0.11	0.59	3.23	1.68	0.64	0.33	2.91	2.18
	-2.14	-3.88	3.28	4.26	0.12	-1.69	5.42	4.35	1.22	0.76	7.89	4.83
	-0.40	-0.72	0.67	0.87	0.03	-0.35	1.11	0.89	0.25	0.16	1.62	0.99
Key metrics
	7.41	3.39	12.74	14.21	8.22	5.81	16.79	13.53	9.71	8.86	16.95	12.29
	7.10%	3.60%	12.40%	13.20%	9.30%	8.10%	15.50%	14.20%	10.80%	10.80%	14.40%	12.80%
	-2.10%	-4.20%	3.20%	4.00%	0.10%	-2.40%	5.00%	4.60%	1.40%	0.90%	6.70%	5.00%
	0.30%	—	2.30%	—	1.10%	—	3.90%	—	—	—	—	—
	17.90%	30.30%	-5.20%	13.00%	-1.50%	-12.90%	-7.60%	-0.40%	—	—	—	—
	-1,883.30%	-129.60%	-39.50%	-2.10%	-90.20%	-322.40%	-31.30%	-9.90%	—	—	—	—

Metric	TTM	FY26	FY25	FY24	FY23	FY22
Income statement
	407.93	370.48	375.64	365.47	396.53	329.49
	11.15	11.39	5.62	4.69	6.43	4.51
	419.07	381.87	381.26	370.16	402.96	334.00
	416.84	373.47	363.64	347.12	367.04	314.70
	176.74	163.19	155.00	177.70	164.98	160.61
	5.68	7.47	11.58	7.80	17.39	9.41
	67.77	60.10	56.41	50.81	46.47	38.63
	14.32	13.20	11.39	6.92	5.58	8.31
	21.18	19.37	19.89	14.83	16.13	14.84
	131.36	116.29	108.11	103.12	100.03	92.58
	2.25	8.40	17.61	23.04	35.92	19.30
	0.00	0.00	0.00	—	—	—
	2.25	8.40	17.61	23.04	35.92	19.30
	3.81	2.44	5.87	6.28	10.91	6.28
	1.52	5.97	11.74	16.76	25.01	13.01
	0.42	1.22	2.41	3.44	5.13	8.01
Key metrics
	37.75	40.97	48.89	44.79	57.63	42.45
	9.25%	11.10%	13.00%	12.30%	14.50%	12.90%
	0.37%	1.60%	3.10%	4.60%	6.30%	3.90%
	—	6.40%	9.70%	—	—	—
	12.15%	-1.40%	2.80%	-7.80%	20.30%	—
	-81.46%	-49.10%	-30.00%	-33.00%	92.20%	—
	—	6.03	12.68	—	—	—
	—	7.98	4.31	—	—	—
	—	0.43	0.46	—	—	—
	—	104.19	111.80	—	—	—
	—	107.9	105.2	—	—	—
Balance sheet
	—	525.20	464.39	—	—	—
	—	252.43	216.35	—	—	—
	—	18.80	0.36	—	—	—
	—	92.28	93.68	—	—	—
	—	93.77	86.47	—	—	—
	—	28.89	35.07	—	—	—
	—	156.37	158.28	—	—	—
	—	76.58	71.87	—	—	—
	—	186.01	166.20	—	—	—
	—	122.99	112.16	—	—	—
	—	81.40	71.86	—	—	—
	—	41.59	40.30	—	—	—
	—	286.35	244.51	—	—	—
Cash flow
	—	47.66	50.60	—	—	—
	—	-57.41	-41.31	—	—	—
	—	28.19	-9.10	—	—	—
	—	41.63	37.92	—	—	—

Compounded growth

Standalone

Sales CAGR 3Y: -2.24%
Sales CAGR 5Y: —
Profit CAGR 3Y: -37.97%
Profit CAGR 5Y: —
Sales YoY (TTM): +12.15%
Profit YoY (TTM): -81.46%

Consolidated

Sales CAGR 3Y: -2.06%
Sales CAGR 5Y: —
Profit CAGR 3Y: -37.94%
Profit CAGR 5Y: —
Sales YoY (TTM): +13.14%
Profit YoY (TTM): -68.54%

Compounded from reported annual figures. We publish no share-price CAGR: our prices are as-traded, so one would be wrong across every split and bonus issue.

Shareholding as of 30 Sep 2026

Promoter holding: 30.31%

Quarter	September 2026	June 2026	March 2026
Promoter %	30.31%	30.35%	30.35%

Holder	Type	Holding	Previous	Change
Anwar Siraj Daud	Promoter	25.03%	25.07%	-0.04%
Elimath Advisors Private Limited	Public	10.41%	10.43%	-0.02%
Zakir S Vali	Public	9.41%	9.43%	-0.02%
Florintree Trinex Llp	Public	8.88%	8.90%	-0.02%
Investor Education And Protection Fund Authority Ministry Of Corporate Affairs	Public	3.57%	3.58%	-0.01%
Sabbah Zulfiquar Kamal	Promoter Group	2.80%	2.80%	0.00%
Bonanza Business Services Pvt Ltd	Public	2.31%	2.32%	-0.01%
Dr Iguer Abdelmounaim	Public	2.17%	2.18%	-0.01%
Zulfiquar Kamal	Promoter	2.08%	2.08%	0.00%
Quince Infotech And Leasing Private Limited	Public	1.27%	—	—
Jyoti Bharat Sheth	Public	1.23%	1.23%	0.00%
Laadki Trading And Investments Limited	Public	1.23%	1.23%	0.00%
Tata India Pharma & Healthcare Fund	Public	1.18%	1.07%	+0.11%
Hasan Kamal	Promoter Group	0.19%	0.19%	0.00%
Shabbar Siraj Daud	Promoter Group	0.08%	0.08%	0.00%

Public shareholders are disclosed individually only above 1%.

Peer comparison

Company	Mkt cap (₹ Cr)	Price (₹)	P/E	ROCE	Sales YoY	Profit YoY	1Y return
Sun Pharmaceutical Industries Ltd.	4,26,112	1,776.00	38.78	17.90%	+12.13% TTM	+4.79% TTM	+4.92%
Divi's Laboratories Ltd.	2,66,424	10,036.00	91.09	19.00%	+16.35% TTM	+26.84% TTM	+47.61%
Torrent Pharmaceuticals Ltd.	1,79,908	4,730.00	85.71	9.10%	+42.06% TTM	-1.92% TTM	+32.24%
Laurus Labs Limited	1,24,601	2,306.10	93.53	19.70%	+23.03% TTM	+95.38% TTM	+134.59%
Zydus Lifesciences Limited	1,18,703	1,190.00	25.85	19.20%	+21.11% TTM	-2.51% TTM	+22.32%
Dr. Reddy's Laboratories Ltd.	1,14,513	1,372.00	41.50	13.90%	-3.53% TTM	-51.90% TTM	+14.26%
Cipla Ltd.	1,13,110	1,400.10	39.63	14.90%	-0.74% TTM	-47.48% TTM	-6.88%
Mankind Pharma Limited	1,04,631	2,533.15	46.22	13.70%	+13.27% TTM	+27.60% TTM	+6.91%
Aurobindo Pharma Ltd.	97,878	1,701.10	26.38	13.60%	+9.09% TTM	+9.48% TTM	+47.79%
Lupin Ltd	92,145	2,015.00	17.65	28.40%	+24.22% TTM	+20.10% TTM	+0.84%
Glenmark Pharmaceuticals ltd	70,608	2,501.85	39.27	16.20%	+32.94% TTM	+138.48% TTM	+35.48%
Alkem Laboratories Limited	62,054	5,190.00	28.15	18.80%	+13.36% TTM	-5.52% TTM	-8.38%
Abbott India Ltd. S	57,685	27,146.85	35.73	41.90%	+6.29% TTM	+11.18% TTM	-7.56%
Biocon Ltd.	56,061	344.00	134.63	2.90%	+5.70% TTM	-55.37% TTM	-9.53%
Gland Pharma Limited	52,105	3,157.70	46.16	13.70%	+17.57% TTM	+46.55% TTM	+65.09%
Ipca Laboratories Ltd.	50,051	1,973.15	36.40	16.40%	+10.59% TTM	+67.91% TTM	+52.33%
GlaxoSmithkline Pharmaceuticals Ltd.	42,904	2,532.60	37.42	55.40%	+12.12% TTM	+20.03% TTM	-4.84%
Ajanta Pharma Ltd.	41,406	3,313.55	32.79	29.40%	+25.01% TTM	+29.70% TTM	+26.89%
Emcure Pharmaceuticals Limited	41,254	2,174.55	37.75	25.10%	+21.12% TTM	+33.34% TTM	+64.07%
J.B. Chemicals & Pharmaceuticals Lt	38,731	2,412.25	47.77	21.90%	+5.87% TTM	+7.56% TTM	+45.79%
Sai Life Sciences Limited	32,855	1,546.30	90.80	18.10%	—	—	+67.49%
PIRAMAL PHARMA LIMITED	31,659	237.80	-151.21	0.80%	+9.43% TTM	-781.93% TTM	+18.60%
ACUTAAS CHEMICALS LIMITED	30,928	3,777.65	70.51	27.70%	+45.18% TTM	+95.78% TTM	+106.30%
Wockhardt Ltd	30,869	1,899.80	76.22	6.40%	+25.70% TTM	+894.12% TTM	+39.18%
RUBICON RESEARCH LIMITED	28,416	1,716.55	98.59	24.30%	—	—	+164.06%
ZIM Laboratories Limited	722	134.60	348.57	6.10%	+13.14% TTM	-68.54% TTM	+83.58%

Filings & corporate actions

Recent announcements

Pursuant to Regulation 30 of SEBI (LODR) Regulations, 2015, please find enclosed the Earnings Presentation for Q2 & H1 FY27.4 Nov 2026 · Company Update / General
Please find enclosed the financial results for the quarter and half year ended 30th September 20264 Nov 2026 · Result / Financial Results
Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we would like to inform you that the Board of Directors in their meeting held today, ....4 Nov 2026 · Board Meeting / Outcome of Board Meeting
We wish to inform you that Q2 & H1FY27 Earnings Conference Call is scheduled to be held on Thursday, 05th November, 2026 at 11:00 a.m. IST.31 Oct 2026 · Company Update / Analyst / Investor Meet
Zim Laboratories Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 04/11/2026 ,inter alia, to consider and approve the Unaudited Financial Results ....28 Oct 2026 · Board Meeting / Board Meeting
Please find enclosed the Press Release relating to grant of GMP Certification of Compliance by Australia''s TGA to the Company for its manufacturing facility.16 Oct 2026 · Company Update / Press Release / Media Release
Please find enclosed the disclosure under Regulation 30 of SEBI (LODR) Regulations 2015 regarding Credit Rating8 Oct 2026 · Company Update / Credit Rating
Certificate under Regulation 74(5) of SEBI(DP) Regulations 2018 for the quarter ended 30th September,2026 is enclosed herewith .8 Oct 2026 · Company Update / Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
Please find enclosed the intimation regarding the closure of Trading Window28 Sep 2026 · Insider Trading / SAST / Closure of Trading Window
Intimation for incorporation of wholly owned subsidiary18 Sep 2026 · Company Update / Acquisition
Update on completion of investment in the share capitalof ZIM Scientific Office L.L.C. (Step Down Subsidiary) by ZIM Laboratories Limited FZE, wholly owned subsidiary15 Sep 2026 · Company Update / Acquisition
Transcript of Q1 FY27 Earning Conference call12 Aug 2026 · Company Update / Earnings Call Transcript
Please find enclosed the Scrutinizer''s Report and Voting Results of Postal Ballot.12 Aug 2026 · AGM/EGM / Postal Ballot
Please find enclosed the Outcome of Postal Ballot .12 Aug 2026 · AGM/EGM / Postal Ballot
Please find enclosed the disclosure for the Link of Audio recording of Earnings Call Q1FY27.8 Aug 2026 · Company Update / Analyst / Investor Meet
Please find enclosed the copy of Newspaper Publication for the financial results for the quarter ended 30th June 2026.7 Aug 2026 · Company Update / Newspaper Publication
Please find enclosed the disclosure under Regulation 30 of SEBI LODR Regulations regarding Earnings Presentation for Q1 FY 276 Aug 2026 · Company Update / General
Please find enclosed the Unaudited Financial Results for the Quarter ended 30th June 2026.6 Aug 2026 · Result / Financial Results
Please find enclosed the Financial Results for the Quarter ended 30th June 2026.6 Aug 2026 · Board Meeting / Outcome of Board Meeting
Please find attached disclosure under Regulation 30 read with Scheduled III of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 for Earnings Conference Call for ....4 Aug 2026 · Company Update / Analyst / Investor Meet
Zim Laboratories Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 06/08/2026 ,inter alia, to consider and approve Unaudited Financial Results ....31 Jul 2026 · Board Meeting / Board Meeting
Please find enclosed the disclosure newspaper publication regarding intimation to the shareholder regarding transfer of shares to IEPF Authority30 Jul 2026 · Company Update / Newspaper Publication
Please find enclosed the disclosure regarding allotment of equity shares of the Company pursuant to exercise of stock options by the eligible employees under ZIM Laboratories Employee Stock ....13 Jul 2026 · Company Update / Allotment of Equity Shares
Please find enclosed the copy of newspaper publication regarding the Notice of Postal Ballot11 Jul 2026 · Company Update / Newspaper Publication
Certificate under Reg 74(5) of SEBI (DP) Regulations,2018 for the quarter ended 30th June 2026 is enclosed herewith.10 Jul 2026 · Company Update / Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
Please find enclosed the Postal Ballot Notice of the Company, for your reference.10 Jul 2026 · AGM/EGM / Postal Ballot
Disclosure under Regulation 30 of SEBI (LODR) 2015, with respect to schedule of Investor/ Analyst Meeting30 Jun 2026 · Company Update / Analyst / Investor Meet
Disclosure under Regulation 30 of SEBI (LODR) 2015, with respect to schedule of Investor/ Analyst Meeting30 Jun 2026 · Company Update / Analyst / Investor Meet
Disclosure under Regulation 30 of SEBI (LODR) 2015, with respect to schedule of Investor/ Analyst Meeting30 Jun 2026 · Company Update / Analyst / Investor Meet
Please find enclosed the Voting Results under Regulation 44 of SEBI (LODR) Regulations 2015 along with the Scrutinizers Report of the 42nd Annual General Meeting of the Company held on 29th June 202629 Jun 2026 · AGM/EGM / AGM
Please find enclosed the Proceedings of the 42nd Annual General Meeting held on 29th June 2026 along with the Scrutinizers Report.29 Jun 2026 · AGM/EGM / AGM
Please find enclosed the intimation regarding the Closure of trading window25 Jun 2026 · Insider Trading / SAST / Closure of Trading Window
The Exchange has received the disclosure under Regulation 10(6) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Dr Anwar Daud16 Jun 2026 · Insider Trading / SAST / Disclosures under Reg. 10(6) of SEBI (SAST) Regulations, 2011
Disclosure under Regulation 30 of SEBI (LODR) 2015, with respect to schedule of Investor/ Analyst Meeting15 Jun 2026 · Company Update / Analyst / Investor Meet
Please find enclosed the schedule of investor meet to be held on 17th June 2026 at 4:00 pm13 Jun 2026 · Company Update / Analyst / Investor Meet
Please find enclosed Newspaper Publication regarding the 42nd Annual General Meeting.6 Jun 2026 · Company Update / Newspaper Publication
Pursuant to Regulation 36(1)(b) of SEBI(LODR) Regulations 2015 please find enclosed the letter sent to members providing weblink of Annual Report for F.Y. 2025-265 Jun 2026 · Company Update / General
Please find enclosed the Annual Report for the F.Y. 2025-26.5 Jun 2026 · Others / Reg. 34 (1) Annual Report
The Notice of 42nd Annual General Meeting along with the Annual Report for the F.Y 2025-26 is enclosed.5 Jun 2026 · AGM/EGM / AGM
The Exchange has received the disclosure under Regulation 10(5) in respect of acquisition under Regulation 10(1)(a) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, ....5 Jun 2026 · Insider Trading / SAST / Disclosures under Reg. 10(5) in respect of acquisition under Reg. 10(1)(a) of SEBI (SAST) Reg. 2011

Board meetings

4 Nov 2026 Board Meeting - Financial Results
6 Aug 2026 Board Meeting - Financial Results